Wall Street analyst estimates for Onconetix, Inc. (ONCO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-45050.00 | ||
| 2026-08-13 | $-1.28 | $-4505.00 | +100.0% |
| 2026-05-13 | $-6.71 | ||
| 2026-03-12 | $12.58 | ||
| 2025-11-13 | $-31.25 | ||
| 2025-08-14 | $-2.02 | $-204.00 | +99.0% |
| 2025-06-12 | $10.59 | $-348.50 | +103.0% |
| 2025-06-02 | $-340.00 | $-450.50 | +24.5% |
Valuation Ratios
| Price / Book | 0.11 |
| EV / EBITDA | 0.21 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $58465 | $2.5M | $815371 |
| Cost of Revenue | $573 | $3056 | $4890 | $6752 | $1.2M | $1.5M | $182458 |
| Gross Profit | -$573 | -$3056 | -$4890 | -$6752 | -$1.1M | $1.1M | $632913 |
| Research & Development | $60174 | $524908 | $1.3M | $4.1M | $1.9M | $154359 | -$66133 |
| Selling, General & Admin | $819485 | $1.1M | $2.1M | $9.4M | $14.8M | $11.2M | $7.0M |
| Operating Expenses | $879659 | $1.6M | $3.4M | $13.5M | $34.9M | $57.5M | $7.0M |
| Operating Income | -$880230 | -$1.6M | -$3.4M | -$13.5M | -$36.0M | -$56.5M | -$6.3M |
| EBITDA | -$821342 | -$1.6M | -$3.4M | -$13.4M | -$36.7M | -$57.6M | -$13.3M |
| Interest Expense | 0 | 0 | 0 | 0 | $671625 | $1.4M | $751005 |
| Pre-tax Income | -$821915 | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$59.7M | -$14.0M |
| Income Tax | 0 | 0 | 0 | 0 | -$12593 | -$1.0M | $525 |
| Net Income | -$821915 | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
| EPS | $-0.02 | $-0.04 | $-0.09 | $-0.31 | $-25.03 | $-520.93 | $-4.73 |
| EPS (Diluted) | $-0.02 | $-0.04 | $-0.09 | $-0.31 | $-25.03 | $-520.93 | $-4.73 |
| Shares Outstanding (Diluted) | $11372 | $11372 | $11372 | $12632 | $17612 | $113050 | $3.3M |
Price
| Price | $0.66 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AZTR · ENVB · INDP · JSPR · PTIX · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of ONCO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks